• Financials

    Novadiscovery raises series A financing to scale its in silico clinical trial platform – Debiopharm leads the round with EUR 5 million

    Novadiscovery has closed the first 5 million euros of a 7 million euros Series A funding round with Debiopharm. Novadiscovery will use the funding to scale its in silico clinical trial simulation platform Jinkō® in a software as a service (SaaS) model and develop further disease models, enabling its clients to directly conduct their in silico trials, and to develop its presence on the US market, the largest market globally for drug development.

    Read more
  • Conference

    Nova will be in San Francisco for the JP Morgan conference next January

    The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.

    Read more
  • Regulatory

    A regulatory landscape for in silico clinical trials (p.18) [TOPRA]

    Modelling and simulation (M&S) has grown to become a reliable approach to better understand and optimise key decisions related to safety, efficacy, dosing, and special target populations. As both computing power and our understanding of human systems biology improve, the increased use of M&S motivates regulators to consider this new type of digital evidence to support medical device and medicinal drug product development and allow new approaches in clinical trials, in view of increasing the probability of success, reduce costs and accelerate time to patients

    Read more
  • In Silico

    La santé, cible ultime des doubles virtuels [LES ECHOS]

    La complexité de l'anatomie humaine fascine les informaticiens. En reproduisant son fonctionnement, ils ouvrent de nouvelles voies thérapeutiques.

    Read more
  • Poster

    Nova to present a poster in collaboration with Enyo Pharma at AASLD 2019

    Novadiscovery presented at the AASLD (American Association for the study of liver diseases) conference a poster explaining how they helped Enyo Pharma optimize the design of their phase II clinical trial, finding the best treatment combination for HBV infection.

    Read more
  • Conference

    Nova will be in Hamburg for BIO Europe from Nov 11th to 13th

    Come and meet Novadiscovery's team to learn more about in silico clinical trials and understand how virtual patients can help you derisk your drug decision making

    Read more
  • Award

    Nova is one the the 3 nominees of the Prix Galien

    Presented by the Galien Foundation and Business France, the Prix Galien – Medstartup encourages and rewards the most promising startups in healthcare formed through international partnerships between French, Israeli, and north American innovators. The program brings together innovators and stakeholders to facilitate rapid adoption and encourages the diffusion of new technologies to improve the state of human health.

    Read more
  • Regulatory

    Nova meets with the FDA to discuss validation of computational models

    Another interesting meeting with the FDA cardiovascular division to help the french biotech OP2 move its asset toward market approval faster with the support of insilico modeling & simulation. Thank you Voisin Consulting Life Sciences (VCLS) & IDDI for your continuous support !

    Read more
  • Conference

    Nova will attend the 19th Annual Biotech in Europe Forum in Basel from Sept 25th to 26th

    The 19th Annual Biotech in Europe Forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry.

    Read more
  • Regulatory

    Nova meets with the EMA to discuss the future of in silico clinical trials

    Another productive meeting last week with OP2 team, Voisin Consulting Life Sciences (VCLS) & IDDI at the European Medicines Agency (EMA) discussing the future of in silico clinical trials

    Read more
  • In Silico

    Le double virtuel du patient, prochaine révolution de la santé [LES ECHOS]

    Plusieurs jeunes pousses sont dans les starting-blocks pour proposer des solutions dans ce domaine : tels Novadiscovery, qui élabore des modèles mathématiques pour réaliser des essais cliniques in silico, plus rapides et meilleur marché

    Read more
  • Regulatory

    Meeting #2 with the FDA for the MIDD pilot program

    Novadiscovery, along with partners OP2 and Voisin Consulting Life Sciences (VCLS), had another productive discussion at the FDA regarding the use of its in silico platform for clinical trials.

    Read more
  • Conference

    Nova at the Center for Innovation in Medicine in the context of Romanian Presidency at EU Council

    Meet our colleague Alexander Kulesza from Novadiscovery at the high-level Conference "The value of data in oncology" organized by the Center for Innovation in Medicine in the context of Romanian Presidency at EU Council. To fight cancer, there is a need for a true personalized approach for prevention, early detection, diagnosis and treatment. Insilico clinical trials are the way forward to address heterogeneity and complexity of the disease through modeling

    Read more
  • Conference

    Nova will be in Philadelphia for the BIO Convention from June 3rd to 7th

    The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

    Read more
  • Conference

    Nova to present the Knowledge Management module of Jinkō to the scientific community of PLASCAN (Preventing tumor cells plasticity and adaptability).

    A online collaborative platform developed by Nova to organize and share scientific knowledge.

    Read more
  • Conference

    Nova to present its viewpoint on artificial intelligence and immunotherapies

    MabDesign and Lyonbiopole organized a day dedicated to the use of Artificial Intelligence to accelerate the development of Immunotherapies. This event gathered together nearly 80 stakeholders working in Artificial Intelligence applied to health, large groups developing immunotherapies that use these approaches, as well as academic laboratories, start-ups and biotechs that develop the latest innovations in the field. The event highlighted the place of Artificial Intelligence tools from the discovery phases of immunotherapy candidates (drug discovery, early stage, biomarker discovery, NGS), through bioproduction until their use during clinical trials (in silico trials, data management, diagnosis, personalized medicine).

    Read more
  • Regulatory

    Meeting #1 with the FDA for the MIDD pilot program

    Novadiscovery, along with partners OP2Drugs and VoisinConsulting, met with the FDA last week to share its expertise on in silico clinical trials as part of the Agency's Model-Informed Drug Development (MIDD) pilot program.

    Read more
  • Conference

    Nova will be in Vienna for BIO Europe from March 25th to 27th

    Come and meet Novadiscovery's team to learn more about in silico clinical trials and understand how virtual patients can help you derisk your drug decision making

    Read more
  • Conference

    Nova will be in San Francisco for the JP Morgan conference next January

    The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.

    Read more